"versionIdentifier","id","instanceType","uuid:ID","rationale"
"2","StudyVersion_1","StudyVersion","3c8d45d4-4fc3-460a-ac5a-c76a17dba3f4","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
